Highlights

• Several predictors of type 1 diabetes outcomes in young adults after transition from pediatric care have been investigated separately in different studies and in various study participants; the present study assessed these predictors and outcomes in the same individuals.
• The present study shows that poor glycemic control and hospitalization for hyperglycemia track from before to after transition.
• Having less education and the presence of comorbidities increase the risk of poor outcomes in young adults with type 1 diabetes.

Highlights

• Non-alcoholic fatty liver disease (NAFLD) has been associated with cardiovascular disease.
• Mediterranean type 1 diabetes (T1D) patients have a low prevalence of NAFLD, and T1D patients exhibit a low prevalence of subclinical atherosclerosis.
• The present study supports the relationship between NAFLD and subclinical cardiovascular disease even in a Mediterranean area.

Highlights

• Application of the transdermal pectin–insulin patch provides glycemic and hemodynamic control that attenuates the cardiac hypertrophy and cardiac inflammatory markers in diabetes.
• The observations in this study further reflect on cardiovascular hazards associated with subcutaneously administered insulin.
• Accordingly, the overall results of the study suggest that the pectin–insulin patch may be an alternative therapeutic approach in the management of diabetes.

Highlights

• People with diabetes in Sudan have significantly more medical service and medication expenses compared with those without diabetes.
• Participants in the present study with diabetes had more comorbid diseases and experienced more negative effects related to ability to work, grow food, and achieve education.
• The study findings increase awareness of this costly and preventable disease among policy makers and clinicians, and support increased allocation of resources for diabetes prevention and control.
• The findings can be used to develop programs and policies for improved, cost-effective strategies by creating innovative models of alternative funding, such as national health insurance and cost-effective health care delivery.

Highlights

• Using longitudinal data on 747 patients treated with sulfonylurea (SU) from a Phase 3 clinical trial in patients with type 2 diabetes, we found that patients with good glycemic control and higher β-cell reserve at entry are more likely to experience primary SU failure, but less likely to experience secondary SU failure.
• By combining baseline basal disposition index with initial response at the first month of treatment, we can get quick information about the long-term efficacy of SU treatment.

Highlights

• Vitamin D supplementation attenuates the simvastatin-mediated decline in exercise-associated cardiorespiratory fitness and skeletal muscle mitochondrial content in patients with type 2 diabetes.
• It is useful to replete patients with vitamin D before starting statin therapy.

Highlights

• Dipeptidyl peptidase (DPP)-4 inhibitors significantly improved HbA1c levels at 12 weeks in both non-dialysis and dialysis patients, compared with 24 weeks in dialysis patients.
• Mean HbA1c changes induced by DPP-4 inhibitors were equivalent to those induced by sulfonylureas at 52 or 54 weeks.
• However, DPP-4 inhibitors induced fewer symptomatic hypoglycemic events than sulfonylureas at 52 or 54 weeks.